Innovation Pharmaceuticals Inc (IPIX)

[PJ007]

Careful selection of an appropriate drug formulation partner should prove invaluable in expeditiously moving Brilacidin forward for diseases like UC and CD, disorders that remain in need of safe and effective options for millions of patients,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “There is only one new oral medication available today for moderate-to-severe UC, a JAK inhibitor approved last year that recently was the subject of an FDA warning about potentially severe side effects, a treatment disadvantage that is also common to biologic-based IBD therapies. Our aim is to develop a safe competitor with a novel mechanism of action in an oral formulation of Brilacidin with the anticipation that it may achieve similar results to the retention enema version that proved effective in our Phase 2 proof-of-concept study of Brilacidin for UP/UPS. A majority of patients tested achieved clinical remission, as supported by evidence of mucosal healing via endoscopic review. Development of an appropriate oral formulation of Brilacidin will position us to move into clinical testing soon thereafter.”